Dec 2, 2021
MediSieve Presents at the Launch of Innovation to Market Programme at London Business School
MediSieve presented the company’s journey at the launch of LBS's I2M Programme and later listened to an excellent panel with LBS alumni.
London Business School's Innovation to Market Programme is a new course for early-career researchers and MBAs run by Professor Jeff Skinner. The course is available as an MBA elective and is open to external applications free of charge. The course aims to build well-balanced teams around technologies that are ripe for commercialisation by bringing together researchers and MBA students. MediSieve was used as a case study for the programme launch. Its CEO & Founder, Dr George Frodsham, was invited to talk about his journey of spinning out and building a company.
Later that day a panel with fellow LBS alumni from renowned venture capital funds was held. The participants included Miao He from Hadean Ventures, Lavanya Bhamidipati from InHealth Ventures, and Georg Glatz from IQ Capital. The team of MediSieve was glad to take part in the launch of the Innovation to Market Programme and is looking forward to see new exciting companies originate from it.
More about the programme:
https://www.london.edu/faculty-and-research/strategy-and-entrepreneurship/innovation-to-market
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
